Literature DB >> 27428598

To remember: Radiotherapy - a successful treatment for early Dupuytren's disease.

B Eberlein1, T Biedermann2.   

Abstract

Dupuytren's disease (DD) is a common fibroproliferative condition of the hand which tends to cause progressive digital flexion contracture. Therapeutic strategies to treat the disease include radiotherapy, injections of collagenase clostridium histolyticum, needle fasciotomy and extended surgical intervention dependent on involvement and duration of the disease. We have reviewed the literature with the aim to assess the conditions and effects of radiotherapy in DD. In early stages of the disease, radiotherapy resulted in regression of symptoms/a lack of progression found on average in 40% (range 10-85%)/81% (range 50-100%) of the patients with recurrence rates of only 12-31% after long-term follow-up (>4 years). These results proved to be significantly better than in the untreated patients with natural course of the disease (about 50% progression after a follow-up of 5-6 years). Long-term side-effects (skin dryness) are observed on average in one quarter of the patients, but are well tolerated. Local occurrence of malignancies has not been reported yet. Due to severe functional impairment leading to individual suffering and the high economic burden, treatment of DD in early stages is necessary and radiation therapy represents an effective, safe and economic treatment option.
© 2016 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2016        PMID: 27428598     DOI: 10.1111/jdv.13773

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  1 in total

1.  Feasibility of aponeurectomy in combination with perioperative 192Ir high dose rate brachytherapy for Dupuytren's disease.

Authors:  I Frank Ciernik; Philipp Goldschmidt; Markus Wösle; Jochen Winter
Journal:  Strahlenther Onkol       Date:  2021-09-07       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.